Announcements Trials
Browse Landscape

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 6Observational 2

Sponsor

Cancer Type

Tumor-Agnostic 2

Conditions

Neoplasms 2

Interventions

Surveys and Questionnaires 86Blood Specimen Collection 59Interviews as Topic 28Observation 15Data Collection 15Radiotherapy 13Drug Therapy 12Watchful Waiting 11Magnetic Resonance Spectroscopy 11Hematologic Tests 11Exercise 11Quality of Life 9Biopsy 8Specimen Handling 7Therapeutics 6Restraint, Physical 6Magnetic Resonance Imaging 6Focus Groups 6pembrolizumab 5Standard of Care 5Rivaroxaban 5Phlebotomy 5Nivolumab 5Lapatinib 5Immune Checkpoint Inhibitors 5Antineoplastic Agents 5atezolizumab 4apixaban 4Trastuzumab 4Patient Reported Outcome Measures 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Observational × Neoplasms × Acceptance and Commitment Therapy × Clear all
NCT03910296 2022-05-03

Acceptance and Commitment Therapy (ACT) - Based Treatment Development for Cancer Patients Treated for Pain

Dana-Farber Cancer Institute

Completed
10 enrolled
Tumor-Agnostic

Neoplasms

NCT04636346 2020-12-17

COMPASS: A Group ACT Program for Cancer Patients Treated at UCSF

University of California, San Francisco

Completed
129 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡